Melanoma, a malignant cancer originating from melanocytes, exhibits complex molecular heterogeneity driven by variations in gene expression profiles captured through RNA analyses. Recent advancements in RNA sequencing technologies enable detailed exploration of the melanoma transcriptome, revealing potential biomarkers and therapeutic targets.

Key Insights into Melanoma RNA

• RNA Profiling and Transcriptomics in Melanoma: RNA extracted from melanoma tissues, including fresh-frozen and formalin-fixed paraffin-embedded (FFPE) samples, enables profiling of messenger RNA (mRNA), microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). These RNA species regulate tumor biology, immune microenvironment interactions, and metastatic processes.
  • Single-cell RNA sequencing (scRNA-seq) has unraveled distinct immune and tumor cell subsets within melanoma microenvironments that influence patient response to immunotherapies such as immune checkpoint inhibitors.
  • Transcriptomic signatures derived from melanoma tissues identify gene sets predictive of therapeutic responses, including anti-PD1 immunotherapy, facilitating personalized treatment strategies.
• Sources and Quality of RNA: While fresh-frozen tissues are ideal for high-quality RNA extraction, the widespread use of archived FFPE melanoma tissues is increasing due to their availability and linked clinical data. However, FFPE samples pose challenges due to RNA degradation, necessitating optimized extraction and quality assessment protocols for reliable downstream analysis.
• Non-coding RNAs as Biomarkers and Regulators:
  • miRNAs, particularly those extracted from melanoma tissues and circulating plasma, serve as non-invasive biomarkers. For instance, miR-210 is elevated in metastatic melanoma and correlates with disease recurrence and poor prognosis.
  • LncRNAs and circRNAs participate in regulation of tumor growth, immune evasion, and metastasis, presenting opportunities for new diagnostic and therapeutic targets.